The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272

Oncogene

Volumn 26, Issue 34, 2007, Pages 5023-5027

  Minami, Y ^a   Shimamura, T ^a   Shah, K ^a,b   LaFramboise, T ^a,b   Glatt, K A ^a   Liniker, E ^a   Borgman, C L ^a   Haringsma, H J ^a   Feng, W ^a,b   Weir, B A ^a,b   Lowell, A M ^a   Lee, J C ^a,b   Wolf, J ^d   Shapiro, G I ^a,c,e   Wong, K K ^a,c,e   Meyerson, M ^a,b,e   Thomas, R K ^a,b,d  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF COLOGNE   (Germany)

^e DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

ERBB2; Her 2; Kinase inhibitors; Lung cancer; Oncogene mutation; Targeted therapy

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; HKI 272; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER INHIBITION; CANCER RESISTANCE; CARCINOGENESIS; CELL ASSAY; CELL TRANSFORMATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG SENSITIVITY; GENE AMPLIFICATION; GENE MUTATION; GENE OVEREXPRESSION; IC 50; LUNG CANCER; LUNG CARCINOGENESIS; LUNG TUMOR; MALIGNANT TRANSFORMATION; MOUSE; MUTANT; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; WILD TYPE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; GENE AMPLIFICATION; GENES, ERBB-2; HUMANS; LUNG NEOPLASMS; MUTATION; PROTEIN KINASE INHIBITORS; QUINOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTOR, ERBB-2;

MURINAE;

EID: 34547470997     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/sj.onc.1210292     Document Type: Article

References (26)

1. Azam M, Latek RR, Daley GQ. (2003). Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell 112: 831-843.
2. Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson SA. (1987). erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237: 178-182.
3. Engelman JA, Janne PA, Mermel C, Pearlberg J, Mukohara T, Fleet C et al. (2005). ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc Natl Acad Sci USA 102: 3788-3793.
4. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY et al. (2003). Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 21: 2237-2246.
5. Gazdar AF, Kurvari V, Virmani A, Gollahon L, Sakaguchi M, Westerfield M et al. (1998). Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int J Cancer 78: 766-774.
6. Greulich H, Chen TH, Feng W, Janne PA, Alvarez JV, Zappaterra M et al. (2005). Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2: e313.
7. Jiang J, Greulich H, Janne PA, Sellers WR, Meyerson M, Griffin JD. (2005). Epidermal growth factor-independent transformation of Ba/F3 cells with cancer-derived epidermal growth factor receptor mutants induces gefitinib-sensitive cell cycle progression. Cancer Res 65: 8968-8974.
8. Jiang J, Paez JG, Lee JC, Bo R, Stone RM, DeAngelo DJ et al. (2004). Identification and characterization of a novel activating mutation of the FLT3 tyrosine kinase in AML. Blood.
9. Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M et al. (2005a). EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352: 786-792.
10. Kobayashi S, Ji H , Yuza Y, Meyerson M, Wong KK, Tenen DG et al. (2005b). An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res 65: 7096-7101.
11. Kris MG, Natale RB, Herbst RS, Lynch Jr TJ, Prager D, Belani CP et al. (2003). Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290: 2149-2158.
12. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW et al. (2005). Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 102: 7665-7670.
13. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW et al. (2004). Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350: 2129-2139.
14. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S et al. (2004). EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304: 1497-1500.
15. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I et al. (2004). EGF receptor gene mutations are common in lung cancers from 'never smokers' and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101: 13306-13311.
16. Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF et al. (2005). Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2: e73.
17. Perez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D et al. (2004). Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22: 3238-3247.
18. Pierce JH, Arnstein P, DiMarco E, Artrip J, Kraus MH, Lonardo F et al. (1991). Oncogenic potential of erbB-2 in human mammary epithelial cells. Oncogene 6: 1189-1194.
19. Rabindran SK. (2005). Antitumor activity of HER-2 inhibitors. Cancer Lett 227: 9-23.
20. Sharma SV, Gajowniczek P, Way IP, Lee DY, Jiang J, Yuza Y et al. (2006). A common signaling cascade may underlie 'addiction' to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell 10: 425-435.
21. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH , Hirsh V, Thongprasert S et al. (2005). Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132.
22. Shigematsu H, Takahashi T, Nomura M, Majmudar K, Suzuki M, Lee H et al. (2005). Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res 65: 1642-1646.
23. Shimamura T, Ji H, Minami Y, Thomas RK, Lowell AM, Shah K et al. (2006). Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272. Cancer Res 66: 6487-6491.
24. Sordella R, Bell DW, Haber DA, Settleman J. (2004). Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163-1167.
25. Stephens P, Hunter C, Bignell G, Edkins S, Davies H, Teague J et al. (2004). Lung cancer: intragenic ERBB2 kinase mutations in tumours. Nature 431: 525-526.
26. Zhao X, Weir BA, LaFramboise T, Lin M, Beroukhim R, Garraway L et al. (2005). Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res 65: 5561-5570.